[CAR-T Cells in solid tumours: present and future]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Adoptive cell therapy utilizes Chimeric Antigen Receptor T-cells (CAR-T) to target tumor antigens.
• CAR-T therapy has demonstrated significant efficacy in hematological malignancies.
• Solid tumors present unique challenges for CAR-T cell therapy.

Purpose of the Study:

• To review the challenges and advancements in CAR-T cell therapy for solid tumors.
• To highlight the potential of emerging CAR technologies in overcoming current limitations.
• To discuss the importance of understanding CAR-T cell mechanisms for future success.

Main Methods:

• Review of current literature on CAR-T cell therapy in solid tumors.
• Analysis of key challenges including antigen targeting, tumor microenvironment, and trafficking.
• Examination of recent technological advancements in CAR design and engineering.

Main Results:

• Solid tumors exhibit limited target antigen availability and heterogeneity.
• The tumor microenvironment often suppresses CAR-T cell activity.
• Poor CAR-T cell infiltration into solid tumors remains a significant hurdle.

Conclusions:

• Overcoming challenges in antigen selection and tumor microenvironment modulation is crucial for CAR-T efficacy in solid tumors.
• Continued advancements in CAR technology and a deeper understanding of resistance mechanisms are essential.
• CAR-T cell therapy holds significant future potential for treating solid tumors.